Prospective, Post Marketing Surveillance of GOOFICE

Prospective, Post Marketing Surveillance of GOOFICE 5mg Tablet

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080223950

Enrollment

3000

Registered

2018-06-20

Start date

2018-06-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic constipation

Interventions

investigational material(s) Generic name etc : GOOFICE 5mg Tablet INN of investigational material : Elobixibat Therapeutic category code : 235 Purgatives and clysters Dosage and Administration for Inv

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic constipation

Exclusion criteria

Exclusion criteria: Off-label set

Design outcomes

Primary

Measure	Time frame
safety Bowel movement frequency Evaluate the change of bowel movement frequency before and after the administration	—

Secondary

Measure	Time frame
efficacy Intervals between a dose and defecation, stool consistency evaluated according to Bristol Stool Form Scale, sensation of satisfactory bowel emptying, etc. Evaluate the difference in measurement before and after the administration	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026